- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06259019
Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease (BIOPATTERN)
Site of Disease BIOmolecule Capture and Analysis in PATienTs With Established Coronary Disease undERgoing iNtracoronary Assessment
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Clinical Project Manager
- Phone Number: 01223638000
- Email: papworth.biopattern@nhs.net
Study Contact Backup
- Name: PlaqueTec General Manager
- Email: simon@plaquetec.com
Study Locations
-
-
-
Bournemouth, United Kingdom
- Recruiting
- Royal Bournemouth Hospital
-
Contact:
- Principal Investigator
- Email: peter.o'kane@uhd.nhs.uk
-
Bristol, United Kingdom
- Recruiting
- Bristol Heart Institute
-
Contact:
- Principal Investigator
- Email: tom.johnson@uhbw.nhs.uk
-
Cambridge, United Kingdom
- Recruiting
- Royal Papworth Hospital
-
Contact:
- Principal Investigator
- Email: steve.hoole@nhs.net
-
Norwich, United Kingdom
- Recruiting
- Norfolk and Norwich Hospital
-
Contact:
- Principal Investigator
- Email: alisdair.ryding@nnuh.nhs.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Stage 1 screening inclusion:
- ≥18 years of age, have capacity and be willing to provide informed consent to participate
Clinical evidence of obstructive coronary artery disease and be scheduled for either:
- Elective coronary angiography +/- proceed for stable angina OR
- Elective PCI for stable angina with known bystander disease not for PCI OR
- Angiography +/- proceed for Troponin negative unstable angina
Stage 2 screening inclusion:
Suitable lesion identified meeting angiographic criteria for LBS deployment and Cardiologist comfortable to deploy OCT and LBS on study lesion before carrying out PCI on any other lesion
Exclusion Criteria:
Stage 1 screening exclusion:
- Myocardial Infarction within 30 days of procedure.
- Chronic renal failure (eGFR<30ml/min/1.73m2).
- Contrast allergy.
- Hypotension, shock or haemodynamic instability.
- Ventricular arrhythmia.
- Chronic Heart Failure (NYHA ≥ 3) or LVEF ≤ 30%.
- Immunocompromised or receiving immunosuppressant therapy.
- Any active disease that in the opinion of the investigator makes the subject unsuitable for the research procedure or subject life expectancy less than 1 year.
- Active infection or sepsis (significant CRP elevation and/or requiring antibiotics).
- Active systemic inflammatory condition.
- Inability to receive anticoagulants or antiplatelets or uncorrected bleeding disorder or deranged platelet count.
- Is pregnant.
- Deemed high clinical risk or unsuitable for the procedure for any reason by the treating clinician.
Stage 2 screening exclusion:
- Target lesion is in the left main coronary artery.
- Target lesion requires PCI
- In same vessel as lesion requiring PCI
- Unsuitable coronary anatomy (vessel tortuosity [>45 degree bend], moderate/ severe calcification angiographically, ostial disease).
- Presence of thrombus in the target vessel.
- Prior PCI or stent in vessel identified for LBS sampling
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Liquid Biopsy System
Main trial arm, all recruited and enrolled patients will undergo intracoronary blood sampling using the Liquid Biospy System Device.
|
Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Trans-plaque gradients (downstream value divided by upstream value) for LOX-1 and CXCL1
Time Frame: Single time point (time of intervention)
|
Single time point (time of intervention)
|
|
Liquid Biopsy System (LBS) performance: successful positioning and successful intracoronary sampling
Time Frame: Single time point (time of intervention)
|
Success define as confirmed adequate positioning of the device across the identified lesion of interest and collection of sufficient whole blood from each functional port to generate >100µl plasma once processed
|
Single time point (time of intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlations between primary outcome measure proteins and: patient subsets and lesion level data
Time Frame: Single time point (time of intervention)
|
Patient level subsets:
Lesion level data: - Coronary fibroatheroma cap thickness and lipid arc as measured by OCT image analysis |
Single time point (time of intervention)
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events in subjects in whom the LBS is used
Time Frame: During intervention and subsequent 30 days
|
During intervention and subsequent 30 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steve Hoole, Royal Papworth Hospital NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 65112021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Liquid Biopsy System (LBS)
-
Sheffield Teaching Hospitals NHS Foundation TrustWithdrawnNon ST Segment Elevation Acute Coronary SyndromeUnited Kingdom
-
Odense University HospitalNot yet recruitingProstate Cancer (Diagnosis)
-
Dana-Farber Cancer InstituteHarvard University; Conquer Cancer Foundation; Alex's Lemonade Stand Foundation; Sam Day FoundationRecruitingEwing Sarcoma of Bone | Ewing Sarcoma | Peripheral Primitive Neuroectodermal Tumor | Peripheral Primitive Neuroectodermal Tumor of Bone | High-grade Osteosarcoma | Ewing Sarcoma of Soft Tissue | Peripheral Primitive Neuroectodermal Tumor of Soft TissueUnited States
-
Helse Nord-Trøndelag HFNorwegian University of Science and TechnologyNot yet recruiting
-
Boehringer IngelheimUniversitätsklinikum Kiel, Onkologisches ZentrumRecruitingColorectal Cancer | Pancreatic Ductal Adenocarcinoma | Non-Small-Cell Lung CarcinomaGermany
-
University of Campania "Luigi Vanvitelli"RecruitingBreast Cancer | Liquid BiopsyItaly
-
Peking University People's HospitalRecruitingGastrointestinal Stromal Tumors | Minimal Residual DiseaseChina
-
Institut BergoniéRecruitingColorectal Cancer | Non Small Cell Lung CancerFrance
-
Xinqiao Hospital of ChongqingCompleted
-
Xinqiao Hospital of ChongqingCompleted